Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.59 |
| ▸ | APLNR | P35414 | 2/20 | 0.52 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TAS2R14 | Q9NYV8 | 6/20 | 0.48 |
| ▸ | CNR1 | P21554 | 1/20 | 0.47 |
| ▸ | CNR2 | P34972 | 1/20 | 0.47 |
| ▸ | NR1H2 | P55055 | 1/20 | 0.47 |
| ▸ | NR1H3 | Q13133 | 1/20 | 0.47 |
| ▸ | MAPT | P10636 | 1/20 | 0.46 |
| ▸ | PKM | P14618 | 1/20 | 0.46 |
| ▸ | FNTA | P49354 | 4/20 | 0.46 |
| ▸ | FNTB | P49356 | 4/20 | 0.46 |
| ▸ | PGGT1B | P53609 | 3/20 | 0.46 |
| ▸ | LMNA | P02545 | 1/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.46 |
| ▸ | PTGES | O14684 | 1/20 | 0.45 |
| ▸ | TAS2R8 | Q9NYW2 | 1/20 | 0.45 |
| ▸ | CXCR3 | P49682 | 1/20 | 0.45 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20757669 | 0.84 | APLNR (0.47) | MEN1KMT2AAPLNRTAS2R14CNR1 | |
| SCHEMBL20757424 | 0.83 | APLNR (0.46) | MEN1KMT2AAPLNRTAS2R14CNR1 | |
| SCHEMBL23013817 | 0.80 | APLNR (0.45) | APLNRTAS2R14CNR1CNR2MAPT | |
| SCHEMBL20760648 | 0.80 | APLNR (0.47) | APLNRTAS2R14CNR1CNR2PTGES | |
| SCHEMBL22497172 | 0.80 | APLNR (0.47) | APLNRTAS2R14CNR1CNR2PTGES | |
| SCHEMBL20760754 | 0.80 | APLNR (0.47) | APLNRTAS2R14CNR1CNR2PTGES | |
| SCHEMBL23012461 | 0.79 | TAS2R14 (0.46) | APLNRTAS2R14CNR1CNR2PTGES | |
| SCHEMBL20757507 | 0.77 | APLNR (0.54) | APLNRTAS2R14CNR1CNR2MAPT | |
| SCHEMBL20743313 | 0.77 | APLNR (0.54) | APLNRTAS2R14CNR1CNR2MAPT | |
| SCHEMBL20609757 | 0.77 | APLNR (0.49) | APLNRTAS2R14MAPTPKMLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11926600-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2024-03-12 | — | — | US | disclosed |
| US-11613542-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2023-03-28 | — | — | US | disclosed |
| US-11542255-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | INFLAZOME LIMITED (IE) | 2023-01-03 | — | — | US | disclosed |
| US-20210130329-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-05-06 | — | — | US | disclosed |
| US-20210130359-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-05-06 | — | — | US | disclosed |
| US-20210130359-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-05-06 | — | — | US | disclosed |
| US-20210122716-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2021-04-29 | — | — | US | disclosed |
| WO-2019034692-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034693-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
| WO-2019034690-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | INFLAZOME LIMITED (IE) | 2019-02-21 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11542255-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | NLRP3, NOD1, PYCARD | MEN1 3382/4885KMT2A 3164/4885APLNR 3397/4885 |
| US-20210130359-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | NLRP3, NOD1, NLRP1 | MEN1 2600/4885KMT2A 2978/4885APLNR 3162/4885 |
| US-20210130329-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | NLRP3, NOD1, PYCARD | MEN1 3382/4885KMT2A 3164/4885APLNR 3397/4885 |
| US-11926600-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | NLRP3, NOD1, NLRP1 | MEN1 2595/4885KMT2A 3259/4885APLNR 3932/4885 |
| US-11613542-B2 | Sulfonylureas and sulfonylthioureas as NLRP3 inhibitors | NLRP3, NOD1, NLRP1 | MEN1 2600/4885KMT2A 2978/4885APLNR 3162/4885 |
| US-20210122716-A1 | SULFONYLUREAS AND SULFONYLTHIOUREAS AS NLRP3 INHIBITORS | NLRP3, NOD1, PYCARD | MEN1 2474/4885KMT2A 3660/4885APLNR 3503/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.